ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Allergy Immunotherapy Market Size and Trends

Global allergy immunotherapy market is estimated to be valued at USD 2,495.8 Mn in 2024 and is expected to reach USD 4,739.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global allergy immunotherapy market is expected to witness significant growth over the forecast period due to  increasing prevalence of allergies such as allergy to pollen, dust, pet dander, insects bites and food allergies across the globe. Allergies have emerged as one of the major health issues affecting people of all age groups. Moreover, the development and approval of novel products such as sublingual and subcutaneous immunotherapy is expected to provide growth opportunities for market players. However, side effects associated with allergy immunotherapy and lack of awareness about available treatment options in developing countries can hamper the market growth during the forecast period.

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.

Basic and clinical research over the past decade has significantly expanded knowledge of how allergen immunotherapy works at the molecular level to provide long-lasting relief. Its complex effects on immune cells, cytokines and antibodies responsible for modifying the body's response to allergens are now increasingly well characterized. This growing scientific evidence base is enabling refinement and targeting of immunotherapy protocols. It is also translating to demonstrable real-world advantages over existing symptomatic therapies which treat only a fraction of patients successfully. Studies following thousands of patients for many years now prove immunotherapy can prevent new sensitizations from developing in addition to treating existing ones. Multiple long-term outcome studies also confirm that its benefits endure for 3-5 years after discontinuation of treatment. This disease-modifying impact sets it apart and raises expectations of altering the natural history of allergy in susceptible individuals